Kaplan-Meier estimates of DFS and OS. Based on induction therapy, cytogenetic risk and received autologous HCT. Data from the subset analysis are shown for DFS (A) and OS (B) for patients who received protocol-prescribed autologous HCT based on the induction therapy standard (45 mg/m²) or high-dose (90 mg/m²) and on cytogenetic risk group. The analysis is regardless of the addition of GO during consolidation. Data are from the time of randomization at the start of transplantation. CNSR indicates censured.